Published in Am J Trop Med Hyg on October 01, 2002
A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med (2005) 2.50
Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun (2002) 1.46
Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection. Genes Immun (2007) 1.14
Genetic predisposition to self-curing infection with the protozoan Leishmania chagasi: a genomewide scan. J Infect Dis (2007) 1.09
Development of recombinant chimeric antigen expressing immunodominant B epitopes of Leishmania infantum for serodiagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol (2005) 1.09
Genome-wide scan for visceral leishmaniasis susceptibility genes in Brazil. Genes Immun (2006) 1.08
Recombinant leishmania antigens for serodiagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol (2005) 1.03
Inaccuracy of enzyme-linked immunosorbent assay using soluble and recombinant antigens to detect asymptomatic infection by Leishmania infantum. PLoS Negl Trop Dis (2009) 0.93
Towards a more precise serological diagnosis of human tegumentary leishmaniasis using Leishmania recombinant proteins. PLoS One (2013) 0.92
The emergence of concurrent HIV-1/AIDS and visceral leishmaniasis in Northeast Brazil. Trans R Soc Trop Med Hyg (2011) 0.90
Leishmania infantum chagasi in northeastern Brazil: asymptomatic infection at the urban perimeter. Am J Trop Med Hyg (2012) 0.90
Identification and diagnostic utility of Leishmania infantum proteins found in urine samples from patients with visceral leishmaniasis. Clin Vaccine Immunol (2012) 0.89
Characterization of novel Leishmania infantum recombinant proteins encoded by genes from five families with distinct capacities for serodiagnosis of canine and human visceral leishmaniasis. Am J Trop Med Hyg (2011) 0.87
Arboprotozoae. Transfus Med Hemother (2009) 0.86
Preventing zoonotic canine leishmaniasis in northeastern Brazil: pet attachment and adoption of community Leishmania prevention. Am J Trop Med Hyg (2012) 0.85
Cutaneous and presumed visceral leishmaniasis in a soldier deployed to Afghanistan. MedGenMed (2006) 0.84
Cytokine responses to novel antigens in a peri-urban population in Brazil exposed to Leishmania infantum chagasi. Am J Trop Med Hyg (2012) 0.83
Leishmania chagasi T-cell antigens identified through a double library screen. Infect Immun (2006) 0.83
Association of pro-inflammatory cytokines and iron regulatory protein 2 (IRP2) with Leishmania burden in canine visceral leishmaniasis. PLoS One (2013) 0.83
A member of the Ras oncogene family, RAP1A, mediates antileishmanial activity of monastrol. J Antimicrob Chemother (2013) 0.77
Appropriate screening for leishmaniasis before immunosuppressive treatments. Emerg Infect Dis (2009) 0.76
Dual immune modulatory effect of vitamin A in human visceral leishmaniasis. PLoS One (2014) 0.76
Detection of IgG Anti-Leishmania Antigen by Flow Cytometry as a Diagnostic Test for Cutaneous Leishmaniasis. PLoS One (2016) 0.75
Improving serodiagnosis of human and canine leishmaniasis with recombinant Leishmania braziliensis cathepsin l-like protein and a synthetic peptide containing its linear B-cell epitope. PLoS Negl Trop Dis (2015) 0.75
Development and Validation of a PCR-ELISA for the Diagnosis of Symptomatic and Asymptomatic Infection by Leishmania (Leishmania) infantum. J Trop Med (2017) 0.75
New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas. Drug Dev Res (2011) 0.75
Anti-leishmania infantum IgG antibody avidity in visceral leishmaniasis. Clin Vaccine Immunol (2013) 0.75
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Illness after international travel. N Engl J Med (2002) 3.56
GeoSentinel surveillance of illness in returned travelers, 2007-2011. Ann Intern Med (2013) 3.37
The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2006) 2.60
Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol (2004) 2.56
A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med (2005) 2.50
The globalization of healthcare: implications of medical tourism for the infectious disease clinician. Clin Infect Dis (2013) 2.42
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One (2011) 2.39
Transmission of dengue virus without a mosquito vector: nosocomial mucocutaneous transmission and other routes of transmission. Clin Infect Dis (2004) 2.30
Three domains of competency in global health education: recommendations for all medical students. Acad Med (2007) 2.22
Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog (2005) 2.19
Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev (2011) 2.09
Characteristics and treatment of hepatic rupture caused by HELLP syndrome. Am J Obstet Gynecol (2006) 2.06
Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol (2002) 2.05
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med (2010) 2.00
Hepatitis B screening in US travelers seen at the Boston area travel medicine network. J Travel Med (2013) 2.00
Second-generation vaccines against leishmaniasis. Trends Parasitol (2005) 1.99
The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function. Mol Biochem Parasitol (2003) 1.93
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun (2004) 1.90
Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol (2008) 1.70
Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem (2012) 1.67
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis (2012) 1.62
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine (2009) 1.60
Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine (2009) 1.58
A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One (2010) 1.57
Use of multiepitope polyproteins in serodiagnosis of active tuberculosis. Clin Diagn Lab Immunol (2002) 1.54
Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med (2011) 1.53
Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis. Clin Vaccine Immunol (2012) 1.49
Knowledge, attitudes, and practices of US practitioners who provide pre-travel advice. J Travel Med (2014) 1.48
Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol (2011) 1.48
Adjuvants for cancer vaccines. Semin Immunol (2010) 1.48
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces (2009) 1.47
Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun (2002) 1.46
Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol (2007) 1.45
Dengue and chikungunya infections in travelers. Curr Opin Infect Dis (2010) 1.45
Prevention of malaria in long-term travelers. JAMA (2006) 1.44
Prevalence of dengue virus infection in US travelers who have lived in or traveled to dengue-endemic countries. J Travel Med (2013) 1.43
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun (2002) 1.42
Upstream sequence elements direct post-transcriptional regulation of gene expression under stress conditions in yeast. BMC Genomics (2009) 1.42
The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol (2012) 1.39
Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine (2009) 1.39
Breastfeeding travelers: precautions and recommendations. J Travel Med (2010) 1.38
IL6 -174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. J Infect Dis (2006) 1.38
An effect of parasite-encoded arginase on the outcome of murine cutaneous leishmaniasis. J Immunol (2007) 1.35
Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun (2007) 1.34
Activation of TGF-beta by Leishmania chagasi: importance for parasite survival in macrophages. J Immunol (2003) 1.34
Threat of dengue to blood safety in dengue-endemic countries. Emerg Infect Dis (2009) 1.32
Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on transfection efficiency. Biomaterials (2006) 1.30
Novel program of macrophage gene expression induced by phagocytosis of Leishmania chagasi. Infect Immun (2004) 1.29
Bias due to selection of rare variants using frequency in controls. Nat Genet (2011) 1.28
Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis. PLoS Negl Trop Dis (2010) 1.28
Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine (2002) 1.28
Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis. PLoS Pathog (2013) 1.28
Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex. Infect Immun (2006) 1.27
An emerging peri-urban pattern of infection with Leishmania chagasi, the protozoan causing visceral leishmaniasis in northeast Brazil. Scand J Infect Dis (2004) 1.27
Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA (2007) 1.26
Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun (2005) 1.26
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release (2013) 1.25
Adjuvants for human vaccines. Curr Opin Immunol (2012) 1.25
Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun (2006) 1.23
GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis (2011) 1.22
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One (2012) 1.22
Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop (2003) 1.20
Case study for a vaccine against leishmaniasis. Vaccine (2013) 1.19
Identification of Mycobacterium tuberculosis antigens of high serodiagnostic value. Clin Vaccine Immunol (2010) 1.19
Immunological dominance of Trypanosoma cruzi tandem repeat proteins. Infect Immun (2008) 1.18
Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry (2002) 1.16
High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clin Infect Dis (2011) 1.15
Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat Genet (2013) 1.15
Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci U S A (2012) 1.14
Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol (2010) 1.14
Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. Vaccine (2010) 1.13
Potential serological use of a recombinant protein that is a replica of a Mycobacterium tuberculosis protein found in the urine of infected mice. Clin Diagn Lab Immunol (2004) 1.13
In vivo imaging of transgenic Leishmania parasites in a live host. J Vis Exp (2010) 1.13
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine (2011) 1.13
Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem (2010) 1.12
Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis (2006) 1.12
Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine (2009) 1.12
Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. J Antimicrob Chemother (2011) 1.11
ML0405 and ML2331 are antigens of Mycobacterium leprae with potential for diagnosis of leprosy. Clin Vaccine Immunol (2006) 1.11
Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis. BMC Infect Dis (2007) 1.11
Illness in long-term travelers visiting GeoSentinel clinics. Emerg Infect Dis (2009) 1.10
Leishmania chagasi: homogenous metacyclic promastigotes isolated by buoyant density are highly virulent in a mouse model. Exp Parasitol (2007) 1.10
Genetic predisposition to self-curing infection with the protozoan Leishmania chagasi: a genomewide scan. J Infect Dis (2007) 1.09
Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins. Infect Immun (2006) 1.09
Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine (2007) 1.09